Dr. Victor Garcia is a current member of the Department of Pharmacology as an Assistant Professor. Prior to returning to NYMC, Dr. Garcia conducted his postdoctoral fellowship at Yale University’s Department of Pharmacology and their Vascular Biology and Therapeutics (VBT) Program under the mentorship of Dr. William Sessa. Dr. Garcia’s research program is focused on the role of the vasoactive cytochrome P450 (CYP)-derived eicosanoid, 20-hydroxyeicosatetraenoic acid (20-HETE) and its recently identified high affinity G-protein coupled receptor (GCR), GPR75. His lab explores and looks to better understand how the 20-HETE/GPR75 pairing is at the root of various pathologies including hypertension, atherosclerosis, myocardial infarction, cancer and cardiometabolic diseases including diabetes and obesity. Dr. Garcia is actively developing and characterizing various preclinical drugs that target GPR75 to potentially treat these various pathologies. In addition to his research program, Dr. Garcia is the Director of the Associated Medical Schools of New York (AMSNY) and NYMC School of Medicine (SOM) linkage program. The goal of this program is to expand the pool of students ethnically/racially underrepresented in medicine and/or who come from educationally/economically disadvantaged backgrounds.

• Pharmacology

• Remond MC, Iaffaldano G, O’Quinn MP, Mezentseva NV, Garcia V, Harris BS, Gourdie RG, Eisenberg CA, and Eisenberg LM. (2011). GATA6 reporter gene reveals myocardial phenotypic heterogeneity that is related to variations in gap junction coupling. American Journal of Physiology: Heart and Circulatory Physiology. Sep 2011. PMCID: 3213955.
• Cheng J, Garcia V, Ding Y, Wu CC, Thakar K, Falck JR, Ramu E, and Schwartzman M.L. Induction of Angiotensin-Converting Enzyme and Activation of the Renin-Angiotensin System Contributes to 20-Hydroxyeicosatetranoic Acid-Mediated Endothelial Dysfunction. Atherosclerosis, Thrombosis, and Vascular Biology (ATVB). Aug 2012. PMCID: 3418056.
• Wu CC, Gupta T, Garcia V, Ding Y, and Schwartzman ML. 20-HETE and Blood Pressure Regulation: Clinical Implications. Cardiology in Review. April 2013. PMCID: 4292790.
• Wu CC, Mei, S, Cheng J, Ding Y, Weidenhammer A, Garcia V, Zhang F, Gotlinger K, Manthati VL, Falck JR, Capdevila JH, and Schwartzman M.L. Androgen-Sensitive Hypertension Associates with Upregulated Vascular Cyp4a12-20-HETE Synthase. Journal of the American Society of Nephrology. May 2013. PMCID: 3736709.
• Ding Y, Wu CC, Garcia V, Dimitrova I, Weidenhammer A, Joseph G, Zhang F, Manthati VL, Falck JR, Capdevila JH, and Schwartzman ML. 20-HETE induces remodeling of renal resistance arteries independent of blood pressure elevation in hypertension. American Journal of Physiology: Renal Physiology July 2013. PMCID: 3761206.
• Cheng J, Edin ML, Li H, Bradbury JA, Graves JP, DeGraff LM, Lih FB, Garcia V, Shaik JSB, Tomer KB, Falck JR, Lee CR, Poloyac SM, and Schwartzman ML, Zeldin DC. Vascular characterization of mice with endothelial expression of Cytochrome P450 4F2. The FASEB Journal. March 2014. PMCID: 4062824.
• Gangadhariah MH, Luther JM, Garcia V, Paueksakon P, Hayward S, Love HD, Falck JR, Manthati VL, Imig JD, Schwartzman ML, Zent R, Capdevila JH, and Pozzi A. Hypertension is a major contributor of 20-hydroxyeicosatetraenoic acid-mediated kidney injury in diabetic Cyp4a14-null male mice. Journal of the American Society of Nephrology (JASN). June 2014. PMCID: 4341468.
• Garcia V, Cheng J, Weidenhammer A, Ding Y, Wu CC, Zhang F, Gotlinger K, Bernstein KE, Falck JR, Dakarapu R, Capdevila J, and Schwartzman ML. Androgen-induced hypertension in angiotensinogen deficient mice: Role of 20-HETE and EETs. Prostaglandins and Other Lipid Mediators (POLM). December 2014. PMCID: 4385421.
• Hoopes SL, Garcia V, Edin ML, Schwartzman ML, and Zeldin, DC. Vascular actions of 20-HETE. Review. Prostaglandins and Other Lipid Mediators (POLM). February 2015. PMCID: 4575602.
• Garcia V, Joseph G, Shkolnik B, Ding Y, Zhang F, Gotlinger K, Bernstein KE, Falck JR, Dakarapu R, Capdevila J, and Schwartzman ML. Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology. April 2015. PMCID: 4491537.
• Wu CC, Gupta T, Garcia V, Ding Y, and Schwartzman ML. 20-HETE and Blood Pressure Regulation: Clinical Implications. Cardiology in Review. April 2013. PMCID: 4292790.
• Dordea A, Vandenwijngaert S, Garcia V, Tainsh R, Nathan D, Allen K, Raher M, Tainsh L, Zhang FF, Lieb W, Mikelman S, Kirby A, Stevens C, Thoonen R, Hindle A, Sips P, Falck JR, Daly M, Brouckaert P, Bloch P, Malhotra, Schwartzman ML, Buys E, and Bloch D. Androgen-sensitive hypertension associated with soluble guanylate cyclase alpha1 deficiency is mediated by 20-HETE. AJP-Heart and Circulatory Physiology. June 2016. PMCID: 4935526.
• Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang F, Dakarapu R, Gandham SK, Reddy R, Graves JP, Gruzdev A, Zeldin D, Capdevila J, Falck JR, and Schwartzman ML. 20-HETE signals through G protein-coupled receptor GPR75 (Gq) to affect vascular function and trigger hypertension. Circulation Research. June 2017. PMCID: 5446268.
• Garcia V, and Schwartzman ML. Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid. Current Opinion in Nephrology and Hypertension. February 2017. PMID: 27906746.
• Garcia V, and Schwartzman ML. Recent developments on the vascular effects of 20-hydroxyeicosatetraenoic acid. Current Opinion in Nephrology and Hypertension. February 2017. PMID: 27906746.
• Pandey V, Garcia V, Gilani A, Mishra P, Zullo J, Jiang H, Falck JR, Nasjletti A, and Schwartzman ML. The blood pressure lowering effect of 20-HETE blockade in Cyp4a14 (-/-) mice is associated with natriuresis. Journal of Pharmacology and Experimental Therapeutics. December 2017. PMCID: 5698946.
• Gilani A, Pandey V, Garcia V, Agostinucci K, Singh S, Schragenheim J, Bellner L, Falck JR, Paudyal M, Capdevila J, Abraham N, and Schwartzman ML. High fat diet-induced obesity and insulin resistance in Cyp4a14-/- mice is mediated by 20-HETE. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. August 2018. PMCID: 6295494.
• Garcia V and William C. Sessa. Endothelial Nitric Oxide Synthase (eNOS): Perspective and Recent Developments. British Journal of Pharmacology. October 2018. PMCID: 6295413.
• Li C, Tang S, Zhang F, Garcia V, Falck JR, Schwartzman ML, Arbad A, and Guo A. CYP4A/20-HETE Axis Regulates Ischemia-induced Neovascularization via Its Actions on Endothelial Progenitor and Preexisting Endothelial Cells. AJP-Heart and Circulatory Physiology. April 2019. PMCID: 6620690.
• Dakarapu R, Errabelli R, Manthati VL, Adebesin AM, Barma DK, Barma D, Garcia V, Zhang F, Schwartzman ML, and Falck JR. 19-Hydroxyeicosatetraenoic acid analogs: Antagonism of 20-Hydroxyeicosatetraenoic acid-induced vascular sensitization and hypertension. Bioorganic and Medicinal Chemistry Letter. August 2019. PMCID: 6745249.
• Garcia V, Park EJ, Siragusa M, Frohlich F, Mahfuzul M, Pascale JV, Heberlein KR, Isakson BE, Stuehr DJ, and Sessa WC. Unbiased proteomics identifies plasminogen activator inhibitor-1 (PAI-1) is a negative regulator of endothelial nitric oxide synthase (eNOS). Proceedings of the National Academy of Sciences (PNAS). April 2020. PMCID: 7196906.
• Gilani A, Agostinucci K, Pascale JV, Hossain S, Kandhi S, Pandey V, Garcia V, Nasjletti A, and Schwartzman ML. Proximal tubular-specific overexpression of the Cyp4a12-20-HETE synthase promotes salt-sensitive hypertension in male mice. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. July 2020. PMCID: 7468799.
• Gilani A, Agostinucci K, Hossain S, Pascale JV, Garcia V, Adebesin AM, Falck JR, and Schwartzman ML. 20-HETE interferes with insulin signaling and contributes to obesity-drive insulin resistance. Prostaglandins and Other Lipid Mediators (POLM). October 2020. PMCID: 7855891.
• Akbari P, Gilani A, Sosina O, Kosmicki J, Khrimian L, Fang Y, Persaud T, Garcia V, Sun D, Li A, Mbatchou J, Locke A, Benner C, Verwejj N, Lin N, Hossain S, Agostinucci K, Pascale JV, Dirice E, Dunn M, Lin N, Regeneron Gegenetics Center, MyCode Consortium, Kraus WE, Shah SH, Chen YI, Rotter JI, Rader DJ, Melander I, Still CD, Mirshahi T, Carey DJ, Torres JM, Emberson J, Collins R, Balasubramanian S, Jones M, Zambrowicz B, Murphy A, Paulding C, Coppola G, Overton J, Reid J, Shuldiner A, Cantor M, Kang HM, Abecasis G, Karalis K, Economides A, Marchini J, Yancopoulus G, Sleeman M, Altarejos J, Della Gatta G, Schwartzman ML. Baras A, Ferreira MA and Lotta LA. Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity. Science. July 2021. PMCID: 34210852.
• Pascale JV, Park EJ, Adebesin AM, Falck JR, Schwartzman ML, and Garcia V. Uncovering the signaling, structure and function of the 20-HETE-GPR75 pairing: Identifying CCL5 as a negative regulator of GPR75. British Journal of Pharmacology (BJP). May 2021. PMCID: 33974269.
• Pascale JV, Lucchesi PA and Garcia V. Unraveling the role of 12- and 20-HETE in cardiac pathophysiology: G-protein coupled receptors, pharmacological inhibitors and transgenic approaches. Journal of Cardiovascular Pharmacology. June 2021. PMCID: 8523029.
• McClung JA, Levy L, Garcia V, Stec DE, Peterson SJ and Abraham NG. Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: therapeutic implications. Pharmacology and Therapeutics. Sept 2021. PMCID: 8958338.
• Agostinucci K, Hutcheson R, Hossain S, Pascale JV, Villegas E, Zhang F, Adebesin AM, Falck JR, Gupte S, Garcia V, and Schwartzman ML. Blockade of 20-HETE Receptor Lowers Blood Pressure and Alters Vascular Function in Mice with Smooth Muscle-Specific Overexpression of CYP4a12-20-HETE Synthase. Journal of Hypertension. March 2022. PMCID: 8820380.
• Froogh G, Garcia V, and Schwartzman ML. The CYP/20-HETE/GPR75 axis in hypertension. Book Chapter. Advances in Pharmacology. Vol 94. March 2022. PMID: 35659370.
• Garcia V. The Importance of “Fit”: An interview with Victor Garcia on vascular biology and enjoying the scientific journey. Nature: Communications Biology. March 2022. PMID: 35292747.
• Li K, Yu XH, Maskey A, Musa I, Wang Z, Garcia V, Guo A, Yang N, Srivastava K, Dunkin D, Li JX, Guo L, Cheng YC, Yuan H, Tiwari R, and Li XM. Cytochrome P450 3A4 Suppression by Epimedium and active compound Kaempferol leads to synergistic anti-inflammatory effect with corticosteroid. Frontiers in Pharmacology. Frontiers in Pharmacology, 2023. PMID: 36793921.
• Pascale JV, Wolf A, Kadish Y, Diegisser D, Kulaprathazhe MM, Yemane D, Ali S, Kim N, Baruch DE, Yahaya MAFB, Dirice E, Adebesin AM, Falck JR, Schwartzman ML, and Garcia V. 20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond. Advances in Pharmacology. March 2023. Book Chapter.
• Hossain S, Gilani A, Pascale JV, Villegas E, Diegisser D, Agostinucci K, Kulaprathazhe MM, Dirice E, Garcia V, and Schwartzman ML. Gpr75-deficient mice are protected from high fat diet-induced obesity. Obesity. February 2023. PMID: 36854900.

No content available to display!!!

No content available to display!!!